避免导管原位癌的过度治疗。

Avoiding Overtreatment of Ductal Carcinoma in situ.

作者信息

van der Borden Carolien L, Stoffers Saskia, Lips Esther H, Wesseling Jelle

机构信息

Division of Molecular Pathology, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

Division of Molecular Pathology, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; Division of Diagnostic Oncology, Department of Pathology, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.

出版信息

Trends Cancer. 2019 Jul;5(7):391-393. doi: 10.1016/j.trecan.2019.05.005. Epub 2019 Jun 20.

DOI:10.1016/j.trecan.2019.05.005

PMID:31311652

Abstract

Ductal carcinoma in situ (DCIS), a precursor to invasive breast cancer (IBC), represents 25% of all breast neoplasms. Most are harmless, but some progress to IBC. Yet, almost all DCIS are treated. Learning how to distinguish harmless from hazardous DCIS will save many women with harmless DCIS the burden of overtreatment.

摘要

导管原位癌（DCIS）是浸润性乳腺癌（IBC）的癌前病变，占所有乳腺肿瘤的25%。大多数是无害的，但有些会发展为浸润性乳腺癌。然而，几乎所有的导管原位癌都得到了治疗。了解如何区分无害的和危险的导管原位癌，将使许多患有无害导管原位癌的女性免于过度治疗的负担。